MarginsXMarginsX
Home › Markets › Health Care › ONCY

Oncolytics Biotech Inc. (ONCY)

ONCY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3399
-8.14% on the day
Market cap
$44.6M
Nano cap
Revenue
No annual revenue filed since the period ending 2021-12-31
Net income
No annual revenue filed since the period ending 2021-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerONCY on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001129928
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials

No annual revenue filed since the period ending 2021-12-31.

Warning signs

Cash runway
2.0 months
$4.1M cash at June 30, 2026
Share count, 1 year
No year-earlier count
+82.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$363K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about our ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$4.1M cash; operating cash flow -$6.1M a quarter.Report 2026-06-30
Shares outstanding136,140,469 (2026-11-13); 74,423,960 three years earlier.Cover page 2026-11-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-06
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-07-24
AuditorErnst & Young LLP, Calgary, Canada; changed auditors 1 time in 24 months8-K 4.01 2026-07-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $363K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$9.4M-$8.1M$4.1MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$9.2M-$7.3M$5.5MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q2 2025
2025-06-30
Not filed-$5.3M-$4.1M$10.7MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$4.7M-$4.7M$10.6MNo debt tagsNeeds four quarters10-Q 2026-05-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-06
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-10-06

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.9%
1 month-24.5%
3 months-53.8%
Year to date-57.5%
1 year-65.7%
From 52-week high-70.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
HYFTMindWalk Holdings Corp.$0.9378-8.95%$44.6M
TLPHTalphera Inc.$0.8609-4.98%$44.7M
NMADNomad Power Solutions Inc.$2.80+19.15%$45.1M
MISTMilestone Pharmaceuticals Inc. Common Shares$0.3650-29.81%$45.4M
RNXTRenovoRx Inc.$0.9549-8.18%$46.1M
PLRXPliant Therapeutics Inc.$0.6932-0.55%$43.0M
ANVSAnnovis Bio Inc.$0.7500-19.02%$46.5M
IBOImpact BioMedical Inc.$4.91-4.47%$42.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier